Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVerona Pharma Share News (VRP)

Share Price Information for Verona Pharma (VRP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.50
Bid: 40.00
Ask: 45.00
Change: 5.00 (13.33%)
Spread: 5.00 (12.50%)
Open: 37.50
High: 42.50
Low: 37.50
Yest. Close: 37.50
VRP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UK WINNERS & LOSERS SUMMARY: RBS Plummets As Dividend Lags Consensus

UK WINNERS & LOSERS SUMMARY: RBS Plummets As Dividend Lags Consensus

14 Feb 20 10:41

Verona Pharma Changes Top Management With New CEO, Finance Head

Verona Pharma Changes Top Management With New CEO, Finance Head

3 Feb 20 14:42

Verona Pharma shares surge after results from latest study

(Sharecast News) - Respiratory disease-focussed biopharmaceuticals company Verona Pharma announced positive top-line data from a four week, 416 patient phase 2b dose-ranging study evaluating nebulised ensifentrine or placebo as an add-on treatment to 'Spiriva Respimat', or tiotropium, which is a long acting anti-muscarinic bronchodilator, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

13 Jan 20 11:08

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

13 Jan 20 10:34

Verona Pharma Says Ensifentrine Study Shows Positive Results

Verona Pharma Says Ensifentrine Study Shows Positive Results

13 Jan 20 07:56

Verona Pharma losses widen as it pours resources into ensifentrine

(Sharecast News) - Biopharmaceutical company Verona Pharma updated the market on its operations and finances for the three and nine months ended 30 September on Tuesday, highlighting positive results from the second part of its phase 2 study of the dry powder inhaler formulation of 'ensifentrine' in chronic obstructive pulmonary disorder (COPD), delivered by handheld inhaler over one week of twice-daily treatment.

5 Nov 19 11:29

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

5 Nov 19 10:38

Verona Pharma Third Quarter Loss Widens On Research & Development

Verona Pharma Third Quarter Loss Widens On Research & Development

5 Nov 19 10:15

Inland Homes snaps up 50% stake in Cheshunt Lakeside Development

(Sharecast News) - Inland Homes on Tuesday acquired a 50% interest in joint-venture partner Cheshunt Lakeside Developments Limited that was held by CPC Group Limited.

29 Oct 19 15:30

Verona Pharma Loss Widens In First Half On Clinical Trial Expenses

(Alliance News) - Verona Pharma PLC on Tuesday said its loss widened in the second quarter and the first half of 2019 as it progressed on clinical trials of Ensifentrine, used for the treatment of

6 Aug 19 12:01

WINNERS & LOSERS SUMMARY: Risk-Off Trade Sends Gold Miners Higher

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 3.1%. The Mexican gold miner rose as the price of

5 Aug 19 10:42

Verona Pharma Shares Jump 15% On Positive Ensifentrine Study Results

(Alliance News) - Verona Pharma PLC on Monday reported positive second phase test data for a dry powder inhaler formulation of its lead development product ensifentrine.The stock was 15% in

5 Aug 19 09:44

Verona Pharma strengthens clinical team ahead of next round of trials

(Sharecast News) - Respiratory-focussed biopharmaceutical company Verona Pharma announced two senior appointments to its clinical team on Tuesday.

25 Jun 19 15:31

Director dealings: Piers Morgan's spouse ups stake in Verona Pharma

(Sharecast News) - Verona Pharma revealed on Wednesday that chief financial officer Piers Morgan's wife Kayt Morgan had acquired 33,802 ordinary shares in the AIM-listed biotechnology outfit.

29 May 19 16:23

Verona Pharma announces next study of nebulised ensifentrine

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a phase 2b dose-ranging study evaluating nebulised ensifentrine (RPL554) added on to a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) on Tuesday.

7 May 19 14:41

Login to your account

Don't have an account? Click here to register.